Climb Bio
Formerly Eliem Therapeutics, a Raven-incubated company

Climb Bio rebranded from Eliem Therapeutics to reflect a new pipeline and mission as a clinical-stage biotech developing budoprutug, an anti-CD19 antibody for B‑cell depletion to treat various immune-mediated diseases. 

Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
NewCo
Initial Investment Year
2016
Climb Bio Portco Hover Image